GE blueprints $165M biologics facilities; Tarveda to partner with Madrigal in $163M deal

GE Healthcare, which has been focusing on reengineering the way biologics are made, is investing $165 million in four turnkey “off the shelf” facilities to be managed by its customers in Ireland. These new facilities will create 500 new jobs.

Months after changing its name from Blend Therapeutics to Tarveda, the rebooted biotech has struck a deal to collaborate with Madrigal Pharmaceuticals on new cancer drugs. Madrigal is in line for up to $163 million in milestones. Madrigal merged into Synta last spring.

Shares of Depomed shot up at the end of last week after Reuters reported that it will be entertaining buyout offers.


Get Endpoints News in your inbox

News reports for those who discover, develop, and market drugs. Join 16,000+ biopharma pros who read Endpoints News articles by email every day. Free subscription.

Quick Subscribe

You're subscribing to Endpoints News

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy